Who are you?
McSAF is a French biotech which develops technologies for stable and homogeneous Antibody-Drug Conjugates (5 proprietary technology patents).
ADC revolutionized the oncological environment and are part of the boiling modalities in targeted therapy.
What is your expertise?
Our innovation focuses on the bioconjugation head, which is compatible with various types of proteins (including native antibodies and fragments), as well as a range of linkers and payloads.
Our approach involves site-specific bioconjugation on cysteine bridges, enabling precise control over the position of the linker and payload in the upper region of the antibody. This method avoids interference with both the Fc and CDR regions.
What are your key products or services?
ADCs cover a wide range of applications and are no longer limited to chemo-type molecules. Our tools are compatible with classic payloads (auristatin, topoisomerase inhibitors, DNA alkylating agents…) and are also compatible with oligonucleotides and radionuclides.
We offer design and production at lab scale of:
- DAR 1, 2, and 4 ADCs
- and DUAL products, carrying two different payloads for complementary mechanism of action
- always with controlled DAR, homogeneity and stability.
Vous souhaitez en savoir plus?
Audrey Desgranges
Director of Operations
audrey.desgranges@mcsaf.fr
(+33) 6 34 63 69 77
Member of
